Kalpit Patel

Stock Analyst at B. Riley Securities

(0)
# 4569
Out of 5,240 analysts
62
Total ratings
29.41%
Success rate
-16.10%
Average return
22 Stocks
Name Action Price Target Current % Upside Ratings Updated
Bicycle Therapeutics
Maintains: Neutral
28 17
14.82 14.71% 6 Dec 13, 2024
Rigel Pharmaceutical...
Maintains: Neutral
27 20
16.68 19.9% 5 Dec 10, 2024
PDS Biotechnology
Maintains: Buy
9 7
1.39 403.6% 5 Nov 25, 2024
Longboard Pharmaceut...
Downgrades: Neutral
45 60
n/a n/a 4 Oct 14, 2024
Corbus Pharmaceutica...
Maintains: Buy
85 40
11.49 248.13% 2 Sep 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
21 7
5.05 38.61% 3 Jul 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
31 36
40.09 -10.2% 2 Jul 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
9 3
0.77 289.61% 2 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
25 20
16.87 18.55% 3 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
3 1
0.46 117.39% 1 Dec 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
65 60
n/a n/a 5 Oct 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
6
3.73 60.86% 5 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
34 36
12.61 185.49% 2 Jul 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
5
2.94 70.07% 2 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
3 2
n/a n/a 1 Nov 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
9 3
0.32 837.5% 3 Nov 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
21 18
1.92 837.5% 2 Sep 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 5
2.36 111.86% 2 Jul 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
12 6
0.17 3429.41% 2 Jun 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
24 10
0.85 1076.47% 1 Jan 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
208 96
n/a n/a 2 Jan 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75
14.57 414.76% 2 Sep 3, 2021